2018
Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett’s Esophagus
Dong J, Levine DM, Buas MF, Zhang R, Onstad L, Fitzgerald RC, Consortium S, Corley DA, Shaheen NJ, Lagergren J, Hardie LJ, Reid BJ, Iyer PG, Risch HA, Caldas C, Caldas I, Pharoah PD, Liu G, Gammon MD, Chow WH, Bernstein L, Bird NC, Ye W, Wu AH, Anderson LA, MacGregor S, Whiteman DC, Vaughan TL, Thrift AP. Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett’s Esophagus. Clinical Gastroenterology And Hepatology 2018, 16: 1598-1606.e4. PMID: 29551738, PMCID: PMC6162842, DOI: 10.1016/j.cgh.2018.03.007.Peer-Reviewed Original ResearchConceptsRisk of EACGastroesophageal reflux diseaseBarrett's esophagusEsophageal adenocarcinomaGERD symptomsWide association studySmoking statusSymptoms of GERDChromosome 1p34.3Environmental factorsChromosome 2p25.1Association of BMIChromosome 1Borderline significant interactionAssociation studiesGene studiesOesophageal cancer studiesSusceptibility lociCase-control logistic regressionGenesChromosome 15q14Genetic variantsReflux diseaseSmoking historyBMI measurements
2017
Determining Risk of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants
Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, Anderson LA, Wu AH, Ye W, Bird NC, Bernstein L, Chow WH, Gammon MD, Liu G, Caldas C, Pharoah PD, Risch HA, Iyer PG, Reid BJ, Hardie LJ, Lagergren J, Shaheen NJ, Corley DA, Fitzgerald RC, consortium S, Whiteman DC, Vaughan TL, Thrift AP. Determining Risk of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. Gastroenterology 2017, 154: 1273-1281.e3. PMID: 29247777, PMCID: PMC5880715, DOI: 10.1053/j.gastro.2017.12.003.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaArea Under CurveAustraliaBarrett EsophagusCase-Control StudiesDatabases, FactualDecision Support TechniquesEsophageal NeoplasmsEuropeFemaleGene-Environment InteractionGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansLife StyleLogistic ModelsMaleMiddle AgedModels, GeneticMolecular EpidemiologyMultifactorial InheritanceNorth AmericaOdds RatioPhenotypePolymorphism, Single NucleotidePredictive Value of TestsRisk AssessmentRisk FactorsROC CurveConceptsGastroesophageal reflux diseaseBarrett's esophagusEsophageal adenocarcinomaLifestyle factorsPolygenic risk scoresGERD symptomsNon-genetic factorsDemographic/lifestyle factorsNet reclassification improvementCharacteristic curve analysisAUC valuesRisk prediction modelEsophageal cancer studyInternational Barrett'sReflux diseaseHighest quartileNet reclassificationEpidemiologic factorsReclassification improvementLowest quartileHigh riskRisk scorePatientsEsophagusAbstractText
2016
Risk Profiles for Barrett’s Esophagus Differ between New and Prevalent, and Long- and Short-Segment Cases
Tan M, Murrey-Ittmann J, Nguyen T, Ketwaroo G, El-Serag H, Thrift A. Risk Profiles for Barrett’s Esophagus Differ between New and Prevalent, and Long- and Short-Segment Cases. PLOS ONE 2016, 11: e0169250. PMID: 28036381, PMCID: PMC5201279, DOI: 10.1371/journal.pone.0169250.Peer-Reviewed Original ResearchConceptsSpecialized intestinal metaplasiaShort-segment BELong-segment BEPrimary care controlsH. pylori infectionRisk factorsGERD symptomsElective esophagogastroduodenoscopyEndoscopy controlsCare controlPylori infectionCase definitionBE casesControl groupGastroesophageal reflux disease symptomsMultivariate logistic regression modelFrequent GERD symptomsPrimary care clinicsCross-sectional studyVeterans Affairs centersLogistic regression modelsEligible patientsH2RA useMedication useCare clinics
2012
Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium
Hoyo C, Cook MB, Kamangar F, Freedman ND, Whiteman DC, Bernstein L, Brown LM, Risch HA, Ye W, Sharp L, Wu AH, Ward MH, Casson AG, Murray LJ, Corley DA, Nyrén O, Pandeya N, Vaughan TL, Chow WH, Gammon MD. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. International Journal Of Epidemiology 2012, 41: 1706-1718. PMID: 23148106, PMCID: PMC3535758, DOI: 10.1093/ije/dys176.Peer-Reviewed Original ResearchConceptsOesophagogastric junction adenocarcinomaBody mass indexGERD symptomsOdds ratioMass indexGastro-oesophageal reflux symptomsStudy-specific odds ratiosInternational BEACON ConsortiumRisk of oesophagealEffect of obesityConfidence intervalsIndividual participant dataReflux symptomsJunction adenocarcinomaOesophagogastric junctionPooled analysisControl subjectsOA casesEffect modificationBMIEpidemiological studiesOesophagealSymptomsPreventive effortsLogistic regression
2008
Eosinophilic Esophagitis: A Prevalent Disease in the United States That Affects All Age Groups
Kapel RC, Miller JK, Torres C, Aksoy S, Lash R, Katzka DA. Eosinophilic Esophagitis: A Prevalent Disease in the United States That Affects All Age Groups. Gastroenterology 2008, 134: 1316-1321. PMID: 18471509, DOI: 10.1053/j.gastro.2008.02.016.Peer-Reviewed Original ResearchConceptsMucosal eosinophil countGastroesophageal reflux diseaseEosinophilic esophagitisHigh-power fieldEosinophil countAge groupsAbdominal pain/dyspepsiaPrevalence of EENational pathology databaseEndoscopy indicationGERD symptomsEosinophilic infiltrationReflux diseaseUpper endoscopyCommon indicationMale predominancePatient's symptomsPathology databaseSingle institutionStudy inclusionEE casesClinical informationNational DiseaseSmall seriesPrevalent disease
2002
Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies
Sugg J, Laine L. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. The American Journal Of Gastroenterology 2002, 97: 2992. PMID: 12492181, DOI: 10.1111/j.1572-0241.2002.07116.x.Peer-Reviewed Original ResearchConceptsPersistent H. pyloriErosive esophagitisGERD symptomsH. pyloriSymptomatic GERDPersistent infectionDouble-blind prospective studyDouble-blind prospective trialGastroesophageal reflux disease symptomsCompletion of therapyDuodenal ulcer diseaseGastroesophageal reflux diseaseHelicobacter pylori eradicationHelicobacter pylori therapyWorsening of symptomsEnd of therapyRapid urease testBlind prospective studyPylori eradicationPylori therapyReflux diseaseRegurgitation scoreProspective trialDuodenal ulcerUlcer disease
2000
Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer
Farrow D, Vaughan T, Sweeney C, Gammon M, Chow W, Risch H, Stanford J, Hansten P, Mayne S, Schoenberg J, Rotterdam H, Ahsan H, West A, Dubrow R, Fraumeni J, Blot W. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes & Control 2000, 11: 231-238. PMID: 10782657, DOI: 10.1023/a:1008913828105.Peer-Reviewed Original ResearchConceptsGastroesophageal reflux diseaseNon-cardia gastric adenocarcinomaEsophageal adenocarcinomaGERD symptomsReflux diseaseH2 blockersGastric adenocarcinomaGastric cancerLarge population-based case-control studyPopulation-based case-control studyPopulation-based tumor registryEsophageal squamous cell carcinomaPerson structured interviewRisk of esophagealSquamous cell carcinomaEsophageal adenocarcinoma riskH2-receptor antagonistsCase-control studyGastric cardia adenocarcinomaRandom digit dialingLong-term usersTumor RegistryAdenocarcinoma riskDaily symptomsCell carcinoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply